OakChart

Protara Therapeutics Inc

TARAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.62+0.19 (7.82%)
2026-11-12 00:29 CET
Market cap
149.62 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-78.44 USD m
Free cash flow, TTM
-73.20 USD m
EPS diluted, TTM
-1.39
P/E
-
Compare

Price

TARA against its 20, 50 and 200-day averages
2050200beatmiss
2.003.004.005.004.4M8.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TARAclose 2.6220-day 2.4250-day 2.95200-day 4.422.6252w low

66.5% under the 52-week high of 7.82 on 24 Nov 2025. 52-week low 2.09 on 6 Nov 2026. Last 15 sessions, 29.2% high to low

Volume 0.77× normal · the line is the 50-bar volume average

Profile

TARA
52-week range, 9% of the way up
2.097.82

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

IndexRUT
Employees51
IPOOct 22, 2014
Beta1.54
ATR, 14d0.20
Rel volume0.77
Short float5.95%
Insider own11.68%
Inst own66.65%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap161.32M
Enterprise Value36.71M
Income-78.44M
Sales0.00M
Book/sh2.35
Cash/sh2.06
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees51
IPOOct 22, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.11
P/C1.27
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.01
Current Ratio9.01
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.39
EPS next Y-1.62
EPS next Q-0.37
EPS this Y-2.80%
EPS next Y-17.32%
EPS next 5Y22.34%
EPS past 3/5Y38.83% 22.18%
Sales past 3/5Y- -
EPS Y/Y TTM4.03%
Sales Y/Y TTM-
EPS Q/Q-10.04%
Sales Q/Q-
EarningsNov 06 BMO
EPS/Sales Surpr.4.29% -

Ownership

Insider Own11.68%
Insider Trans-2.91%
Inst Own66.65%
Inst Trans4.89%
ROA-52.09%
ROE-57.40%
ROIC-55.18%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA208.38%
SMA50-11.15%
SMA200-40.76%
Trades-

Technical

Shs Outstand59.97M
Shs Float54.38M
Short Float5.95%
Short Ratio3.27
Short Interest3.24M
52W High7.82 -66.50%
52W Low2.09 25.36%
Volatility11.62% 7.83%
ATR (14)0.20
RSI (14)51.61
Beta1.54
Rel Volume0.77
Avg Volume990.12K
Volume765,038

Performance

Perf Week11.49%
Perf Month0.00%
Perf Quarter-33.50%
Perf Half Y-49.62%
Perf YTD-50.84%
Perf Year-51.12%
Perf 3Y120.17%
Perf 5Y-64.55%
Perf 10Y-99.26%
Recom1.00
Target Price25.33
Prev Close2.43
Price2.62
Change %7.82%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Mar 04, 2026InitiatedJJP MorganOverweight$27+930.5%
Jan 07, 2026InitiatedPPiper SandlerOverweight$24+816.0%
Apr 16, 2025InitiatedBScotiabankSector Outperform$12+358.0%
Mar 14, 2025InitiatedCCantor FitzgeraldOverweight
Jul 10, 2023ResumedGGuggenheimBuy$22+739.7%
Jun 04, 2021InitiatedHH.C. WainwrightBuy$40+1,426.7%
Feb 17, 2021InitiatedOOppenheimerOutperform$43+1,541.2%
Oct 19, 2020InitiatedCCowenOutperform$50+1,808.4%
Jul 29, 2020InitiatedGGuggenheimBuy$50+1,808.4%

Peers

Mkt cap
TickerCompanyMkt cap
ENGNenGene Therapeutics Inc120.63M
CGONCg Oncology Inc6.49B
IBRXImmunityBio Inc7.10B
URGNUroGen Pharma Ltd1.28B
CADLCandel Therapeutics Inc705.50M
JNJJohnson & Johnson675.03B
PGENPrecigen Inc1.69B
CHRSCoherus Oncology Inc90.02M
TLXTelix Pharmaceuticals Ltd ADR3.31B
IRWDIronwood Pharmaceuticals Inc806.23M

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Shefferman JesseCEO and PresidentJun 29 '26Option Exercise1.91215,687411,962937,519Jul 01 04:10 PM
Shefferman JesseCEO and PresidentJun 29 '26Sale4.09215,687882,160721,832Jul 01 04:10 PM
JESSE SHEFFERMANOfficerJun 29 '26Proposed Sale4.09215,687882,009Jun 29 04:52 PM
Baker Brothers Life Sciences,Former AffiliateApr 23 '26Proposed Sale5.35300,1761,605,942Apr 23 08:42 PM
667, L.P.Former AffiliateApr 23 '26Proposed Sale5.3524,802132,691Apr 23 08:41 PM
Zummo JacquelineChief R&D OfficerApr 08 '26Sale5.401,1346,12494,827Apr 09 05:25 PM
Zummo JacquelineChief R&D OfficerApr 01 '26Sale5.2622,598118,86595,961Apr 02 04:05 PM
Zummo JacquelineOfficerApr 01 '26Proposed Sale5.2623,732124,826Apr 01 10:32 AM
667, L.P.Former AffiliateMar 06 '26Proposed Sale5.8538,277223,920Mar 06 05:51 PM
Baker Brothers Life Sciences,Former AffiliateMar 06 '26Proposed Sale5.85461,7232,701,080Mar 06 05:50 PM
667, L.P.Former AffiliateMar 04 '26Proposed Sale6.2635,173220,151Mar 04 08:37 PM
Baker Brothers Life Sciences,Former AffiliateMar 04 '26Proposed Sale6.26424,1252,654,641Mar 04 08:35 PM
667, L.P.Former AffiliateFeb 25 '26Proposed Sale5.8178,716457,046Feb 25 07:58 PM
Baker Brothers Life Sciences,Former AffiliateFeb 25 '26Proposed Sale5.81947,4795,501,316Feb 25 07:57 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Protara Therapeutics: Q3 Earnings Snapshot (Associated Press) +7.98%
  • Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
  • Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support (GlobeNewswire)
  • Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Protara Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
  • Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA (GlobeNewswire) +9.68%
  • Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 (GlobeNewswire) -9.80%
  • Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naive Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC (GlobeNewswire)
  • Protara Therapeutics: Q1 Earnings Snapshot (Associated Press)
  • Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
  • Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients at the American Urological Association Annual Meeting (GlobeNewswire)
  • Protara Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
  • Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-0.350-0.366-0.3500.000.007
2026Q22026-08-11-0.360-0.326-0.3550.000.007
2026Q12026-05-13-0.310-0.369-0.3090.000.007
2025Q42026-03-10-0.370-0.311-0.3760.000.007
2025Q32025-11-10-0.310-0.384-0.3140.000.005
2025Q22025-08-11-0.350-0.385-0.3540.000.004
2025Q12025-05-08-0.290-0.452-0.2930.000.005
2024Q42025-03-05-0.480-0.565-0.4830.000.002
2024Q32024-11-12-0.500-0.520-0.5020.000.003
2024Q22024-08-06-0.450-0.800-0.4480.000.003
2024Q12024-05-02-0.970-0.920-0.9720.000.004
2023Q42024-03-13-0.900-0.918-0.8990.000.004
2023Q32023-11-03-0.870-0.980-0.8690.000.004
2023Q22023-08-03-1.000-0.875-0.9990.000.004
2023Q12023-05-04-0.800-0.877-0.8000.000.003
2022Q42023-03-08-3.460-0.750-3.4580.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.570-3.980-121.51--
2020FY-4.700-3.780-4.6970.000.00
2021FY-4.210-4.423-4.2070.000.00
2022FY-5.860-3.478-5.8570.000.00
2023FY-3.570-3.572-3.5670.000.00
2024FY-2.170-2.200-2.1660.000.00
2025FY-1.340-1.261-1.3400.000.00
2026FY--1.378--0.00
2027FY--1.616--1.17
2028FY--0.604--65.41
2029FY-0.165--176.54
2030FY-1.193--297.91

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-066000.000.000.00
2026Q4S2026-08-116000.000.000.00
2026Q4S2026-05-136000.000.000.00
2026Q4S2026-04-276000.000.000.00
2026Q4S2026-03-115000.000.000.00
2026Q4S2026-03-104000.000.000.00
2026Q4S2026-02-174000.000.000.00
2026Q4S2026-01-213000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-092000.000.000.00
2026Q4S2025-11-082000.000.000.00
2026Q4S2025-11-072000.000.000.00
2026Q4S2025-11-062000.000.000.00

Estimate history

EPS, annual-85.2-45.804-121.514-4.697-4.207-5.857-3.567-2.166-1.341-1.3852
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.502-0.483-0.293-0.354-0.314-0.376-0.309-0.355-0.345
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.4420.4810.06611.21211.23611.26711.36535.04553.58759.968
Period201720182019202020212022202320242025MRQ
Shares, quarterly20.6335.04538.57838.58238.58753.58755.05659.08459.968
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.330.360.330.340.251.170.200.020.12
Gross Profit-0.33-0.36-0.33-0.34-0.25-1.17-0.20-0.02-0.12
Selling, General and Administrative Excl. Other84.8664.1948.8243.2737.3046.3234.257.8121.26
Research and Development60.1242.4931.5724.7916.6721.0511.883.8611.85
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-85.19-64.55-49.15-43.61-37.55-47.49-34.44-7.83-21.37
Interest Expense0.000.000.000.001.140.00-0.000.00
Unusual Expense0.000.000.000.0029.520.000.000.00-
Net Income Before Taxes-78.44-57.44-44.60-40.42-65.95-47.25-33.98-7.83-20.73
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-78.44-57.44-44.60-40.42-65.95-47.25-33.98-7.83-20.73
Net Income From Continuing Operations-78.44-57.44-44.60-40.42-65.95-47.25-33.98-7.83-20.73
Net Income-78.44-57.44-44.60-40.42-65.95-47.25-33.98-7.83-20.73
EPS (Recurring)-1.25-1.34-2.17-3.57-4.02-4.21-4.70-121.51-45.80
EPS (Basic, Before Extraordinaries)-1.39-1.34-2.17-3.57-5.86-4.21-4.70-121.51-45.80
EPS (Diluted)-1.39-1.34-2.17-3.57-5.86-4.21-4.70-121.51-45.80
EBITDA-84.86-64.19-48.82-43.27-37.30-46.32-34.25-7.81-21.26
Non-Operating Income (Expense)6.747.114.563.192.250.240.470.000.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.383.834.126.096.6910.369.750.423.43
Shares Outstanding59.9753.5935.0411.3611.2711.2411.210.070.48
Market Capitalization149.62149.62181.2121.3130.2075.84271.449.1543.68

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.070.070.090.090.090.100.080.08
Gross Profit-0.07-0.07-0.09-0.09-0.09-0.10-0.08-0.08
Selling, General and Administrative Excl. Other23.0823.2519.5418.9914.6716.4914.0414.23
Research and Development16.7316.8813.4713.039.5010.679.069.50
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.15-23.32-19.63-19.08-14.76-16.59-14.12-14.31
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-21.69-21.67-17.78-17.31-13.26-14.96-11.91-12.77
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-21.69-21.67-17.78-17.31-13.26-14.96-11.91-12.77
Net Income From Continuing Operations-21.69-21.67-17.78-17.31-13.26-14.96-11.91-12.77
Net Income-21.69-21.67-17.78-17.31-13.26-14.96-11.91-12.77
EPS (Recurring)-0.35-0.36-0.31-0.38-0.31-0.35-0.29-0.48
EPS (Basic, Before Extraordinaries)-0.35-0.36-0.31-0.38-0.31-0.35-0.29-0.48
EPS (Diluted)-0.35-0.36-0.31-0.38-0.31-0.35-0.29-0.48
EBITDA-23.08-23.25-19.54-18.99-14.67-16.49-14.04-14.23
Non-Operating Income (Expense)1.471.661.851.771.501.632.211.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.591.381.361.041.050.900.830.90
Shares Outstanding59.9759.0855.0653.5938.5938.5838.5835.04
Market Capitalization149.62214.70281.78275.19167.83116.90156.63181.21

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments155.55170.2965.5884.3791.23168.650.5621.8742.14
Short Term Receivables1.260.000.240.490.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.691.862.881.291.880.790.081.371.34
Total Current Assets159.50172.1668.7086.1593.11169.440.6423.2443.48
Net Property, Plant & Equipment3.935.286.567.878.891.240.460.260.26
Total Investments and Advances43.080.740.7418.6340.210.000.000.000.00
Long-Term Note Receivable-----0.740.00--
Intangible Assets---0.0029.5229.520.000.000.00
Other Assets2.953.272.940.640.862.220.120.020.24
Total Assets209.47181.4578.95113.29172.60203.161.2223.5243.98
Short Term Debt Incl. Current Port. of LT Debt1.241.120.980.920.850.090.000.000.00
Accounts Payable3.474.432.431.590.950.910.720.000.00
Other Current Liabilities6.235.412.733.242.491.912.633.089.24
Total Current Liabilities10.9410.966.155.744.302.923.353.089.24
Long Term Debt2.123.364.485.476.381.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities13.0614.3210.6311.2110.683.913.353.089.24
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.0021.5221.52
Common Equity196.41167.1368.32102.08161.91199.24-2.13-1.0813.22
Total Shareholders Equity196.41167.1368.32102.08161.91199.24-2.1320.4434.74
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity196.41167.1368.32102.08161.91199.24-2.1320.4434.74
Total Liabilities & Stockholders Equity209.47181.4578.95113.29172.60203.161.2223.5243.98
Book Value Per Share3.674.776.019.0614.4117.77-32.40-2.2429.91
Tangible Book Value Per Share3.674.776.019.0611.7815.14-32.40-2.2429.91
Full-Time Employees513327253129121716
Price to Book Ratio1.031.330.280.220.471.36-0.76-40.451.87
Return on Assets-29.39-34.25-42.05-46.14-25.15-32.34-63.29-61.42-68.49
Return on Equity-31.60-37.88-47.44-49.96-26.17-33.05-85.50-75.13-81.89
Return on Invested Capital-28.93-26.16-55.52-61.32-28.08-16.97--101.40-86.25
Quick Ratio14.5815.7111.1715.0121.6658.130.197.554.71
Current Ratio14.5815.7111.1715.0121.6658.130.197.554.71

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-78.44-57.44-44.60-40.42-65.95-47.25-33.98-7.83-20.73
Depreciation0.330.360.330.340.251.170.200.020.12
Other Funds (Non Cash)5.663.654.456.6638.7112.109.750.423.35
Funds from Operations-72.45-53.42-39.81-33.42-27.00-33.99-24.04-7.39-17.26
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.33-2.944.01-4.140.54-0.520.632.38-5.97
Cash from Operating Activities-72.12-56.37-35.81-37.56-26.46-34.50-23.41-5.01-23.23
Capital Expenditures-1.08-0.09-0.06-0.04-0.12-0.60-0.88-0.47-0.12
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.003.720.00-
Purchase or Sale of Investments3.31-139.4019.2253.1515.07-97.600.000.0018.55
Purchase of Investments-137.58-204.63-29.38-12.19-43.55-124.750.000.00-15.44
Sale Or Maturity of Investments140.8865.2348.6065.3458.6227.150.000.0033.99
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities2.23-139.4919.1653.1114.95-98.192.83-0.4718.43
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock82.7982.90139.95-0.09-0.09-0.23191.070.502.98
Repurchase of Common Pref Stock0.000.000.00-0.09-0.09-0.230.000.000.00
Sale of Common Pref Stock82.7982.90139.950.000.000.00191.070.502.98
Proceedsfrom Stock Options82.9582.88136.010.000.000.00179.450.502.98
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-1.670.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.30-0.18-0.080.000.000.000.000.000.00
Other Financing Activities Uses-0.30-0.18-0.080.000.000.000.000.000.00
Cash from Financing Activities82.4982.72139.87-0.09-0.09-0.23189.400.502.98
Exchange Rate Effect-------0.000.02
Net Change in Cash12.60-113.14123.2115.46-11.60-132.92168.83-4.99-1.80
Free Cash Flow-73.20-56.46-35.87-37.60-26.58-35.10-24.29-5.49-23.35
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments127.05142.49135.79155.55132.67122.22
Short Term Receivables1.061.281.521.261.000.89
Inventories0.000.000.000.000.000.00
Other Current Assets1.562.382.692.691.971.99
Total Current Assets129.67146.15140.00159.50135.64125.09
Net Property, Plant & Equipment3.893.923.563.934.284.64
Total Investments and Advances16.7820.1042.3943.081.7024.14
Other Assets6.215.925.982.953.013.07
Total Assets156.54176.09191.92209.47144.64156.93
Short Term Debt Incl. Current Port. of LT Debt1.311.291.261.241.221.20
Accounts Payable4.864.664.033.474.505.30
Other Current Liabilities8.227.373.636.234.183.26
Total Current Liabilities14.3913.328.9210.949.919.76
Long Term Debt1.131.461.792.122.442.75
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities15.5214.7810.7113.0612.3512.51
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity141.02161.31181.21196.41132.29144.42
Total Shareholders Equity141.02161.31181.21196.41132.29144.42
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity141.02161.31181.21196.41132.29144.42
Total Liabilities & Stockholders Equity156.54176.09191.92209.47144.64156.93
Book Value Per Share2.352.733.293.673.433.74
Tangible Book Value Per Share2.352.733.293.673.433.74
Full-Time Employees---51--
Price to Book Ratio1.031.161.421.551.160.74
Return on Assets-52.09-42.05-35.12-29.39-44.32-39.34
Return on Equity-57.40-45.80-37.27-31.60-49.42-43.02
Return on Invested Capital-15.26-13.31-9.72-8.72-9.84-10.16
Quick Ratio9.0110.9715.6914.5813.6912.82
Current Ratio9.0110.9715.6914.5813.6912.82

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.69-21.67-17.78-17.31-13.26-14.96
Depreciation0.070.070.090.090.090.10
Other Funds (Non Cash)1.711.501.460.990.920.80
Funds from Operations-19.91-20.09-16.24-16.22-12.25-14.06
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.474.70-5.11-0.73-0.211.81
Cash from Operating Activities-18.44-15.39-21.34-16.95-12.45-12.25
Capital Expenditures-0.72-0.330.00-0.02-0.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments26.8318.09-14.72-26.88-6.50-47.70
Purchase of Investments-11.78-19.23-43.86-62.71-24.41-51.70
Sale Or Maturity of Investments38.6037.3229.1435.8217.914.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities26.1017.75-14.72-26.91-6.51-47.72
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.410.001.4280.960.010.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.410.001.4280.960.010.01
Proceedsfrom Stock Options0.000.00-0.5383.470.010.01
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.03-0.270.000.000.00
Other Financing Activities Uses0.00-0.03-0.270.000.000.00
Cash from Financing Activities0.41-0.031.1480.960.010.01
Net Change in Cash8.072.34-34.9237.11-18.95-59.97
Free Cash Flow-19.16-15.72-21.34-16.97-12.46-12.27

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.20%3.2M52.2M963.62K
2026-10-1511.68%6.1M52.2M839.55K
2026-09-3011.10%5.8M52.2M715.88K
2026-09-158.46%4.4M52.2M513.77K
2026-08-318.55%4.4M51.8M557.34K
2026-08-148.76%4.5M51.8M658.10K
2026-07-318.90%4.5M50.5M697.12K
2026-07-159.00%4.5M50.5M743.52K
2026-06-308.59%4.3M50.5M711.75K
2026-06-158.82%4.5M50.6M730.14K
2026-05-2911.69%5.9M50.4M786.22K
2026-05-157.42%3.7M50.4M927.89K
2026-04-3011.95%6.0M50.2M910.70K
2026-04-1511.65%5.7M49.3M1.01M
2026-03-3111.32%5.6M49.0M1.13M
2026-03-1313.05%6.4M49.0M1.07M
2026-02-2710.46%4.9M46.8M1.16M
2026-02-137.07%3.3M46.8M1.01M
2026-01-305.98%2.8M47.4M994.15K
2026-01-155.32%2.5M47.4M843.59K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.750.354.4121290.000.674-0.0420.001
call5.000.000.100.012.8369430.000.107-0.0120.001
call7.500.000.600.104.00073.000.000.084-0.0140.001
call10.000.000.750.754.75322.000.000.075-0.0160.001
put2.500.000.750.345.2412430.00-0.326-0.0420.001
put5.001.803.201.108.2530.000.00-0.893-0.0120.001
put7.504.405.703.209.7412.000.00-0.916-0.0130.001
put10.006.908.300.0011.3080.000.00-0.925-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-07SCHEDULE 13G/ASEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-298-KCurrent report2026-06-26SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-158-KCurrent report2026-06-12SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-05-28424B5SEC
2026-05-22EFFECTEffectiveness filing by commission orderSEC
2026-05-20CORRESPSEC
2026-05-19UPLOADUpload SubmissionSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-14S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0600882.16K1
2026-050000
2026-0400124.99K2
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Jupiter Topco LLC8.36%
BlackRock, Inc.6.52%
MILLENNIUM MANAGEMENT LLC5.52%
Velan Capital Investment Management LP5.06%
VANGUARD CAPITAL MANAGEMENT LLC4.09%
Blackstone Inc.4.03%
ORBIMED ADVISORS LLC3.95%
Sio Capital Management, LLC3.42%
ACORN CAPITAL ADVISORS, LLC3.12%
Integral Health Asset Management, LLC2.67%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.95%
iShares Russell 2000 ETF2.43%
Columbia Small Cap Value Discovery Fund1.35%
VANGUARD EXTENDED MARKET INDEX FUND1.04%
Fidelity Small Cap Index Fund1.01%
iShares Russell 2000 Value ETF0.85%
VANGUARD RUSSELL 2000 INDEX FUND0.51%
Fidelity Extended Market Index Fund0.43%
U.S. SMALL CAP PORTFOLIO0.32%
iShares Micro-Cap ETF0.31%

OakChart. TARA. Cached 15 minutes.